Toolkit
HIV Treatment and Care
Frontiers in Pediatrics | www.frontiersin.org
1 April 2019 | Volume 7 | Article 159
The aim of the operational framework is to ensure 1) accurate collection, handling, shipment and storage of specimens collected in countries implementing HIV drug resistance surveillance; and 2) the availability of quality-assured HIV genotyping laboratory services producing comparable and reliable ...results at the national, regional and global levels.
This publication updates the WHO HIVResNet HIV drug resistance laboratory operational framework published in 2017 and reflects technical and strategic developments over the past three years.
more
WHO
Considering programmatic implications of rising levels of HIV drug resistance: finalizing the Global Action Plan
Webinars 12 13 Dec 2016
PQDx 0141-051-00 WHO
PQDx Public Report
April/2017, version 5.0
The five thematic discussion papers in this collection were prepared by members of the Global Prevention Coalition Steering Group and other experts from various institutions and countries. Contributors are listed in alphabetical order. The five papers are meant to inform country consultations and th...e development of a Global HIV Prevention Roadmap. They do not reflect the views of UNAIDS or any other agency or organization.
more
Meeting report
Geneva, 16-18 November 2016
Brussels, December 16. 2016
3rd Edition – July 2017
www.msfaccess.org
UNAIDS 2017 / Reference
Generating evidence for policy and action on HIV and social protection
HIV treatment
Policy brief
July 2017
WHO/HIV/2017.18
The guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection, and at community advocates responsible for promoting the best interests and care of HIV-positive adults. They should be read in conjunction with other published BHIVA ...guidelines.
The 2016 interim update to the 2015 BHIVA antiretroviral guidelines has been published online to include tenofovir-alafenamide/emtricitabine as a preferred NRTI backbone for first-line therapy. Changes were based on new data and the consensus opinion of the writing committee. All changes to the guideline are highlighted and include updates to the chronic kidney disease and bone disease sections of special populations and some small changes to managing virological failure.
The 2019 interim statement provides updated advice on treatment with two-drug regimens
more
Supplement Article
J Acquir Immune Defic Syndr Volume 75, Supplement 2, June 1, 2017 www.jaids.com
1 July 2021; Report shows big COVID-19-related HIV prevention programme service disruptions, but highlights that HIV service innovations and adaptations are possible.
A synthesis report on programme disruptions and adaptations during the COVID-19 pandemic in 2020